Shopping Cart 0
Cart Subtotal
USD 0

Mologen AG (MGN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

Mologen AG (Mologen) is a biotechnology company that offers research and clinical development of novel drugs, immunotherapies and active ingredients. The company develops various pipeline products such as MGN1703, MGN1601, MGN1404, MGN1331 and MGN1333. It uses proprietary platform technologies, dSLIM, EnanDIM, MIDGE vector system, and allogeneic tumor cell bank for the development of medicines and vaccines. Mologen's target therapy area includes oncology and anti infectives, solid tumors, small cell lung cancer, colorectal cancer, leishmaniasis, renal cancer, hepatitis B and malignant melanoma. The company also develops tolerable drugs in fields of oncology and serious infectious diseases. Mologen is headquartered in Berlin, Germany.

Mologen AG (MGN)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Mologen AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Mologen AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Mologen AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Mologen AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Mologen AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Mologen AG, Pharmaceuticals & Healthcare, Deal Details 11

Private Equity 11

Mologen to Raise USD0.6 Million in First Tranche of Private Placement of Bonds 11

Mologen to Raise up to USD14.9 Million in Private Placement of Convertible Bonds 12

Partnerships 13

Mologen Enters into Agreement with The University of Texas MD Anderson Cancer Center 13

Licensing Agreements 14

Oncologie Expands Licensing Agreement with Mologen for lefitolimod 14

iPharma to Enter into Licensing Agreement with Mologen for Lefitolimod 16

Equity Offering 17

Mologen Raises USD2.3 Million in Private Placement of Shares 17

Mologen Raises USD3.8 Million in Rights Offering of Shares 18

Mologen to Raise USD6.2 Million in Rights Offering Shares 19

Mologen Raises USD0.7 Million in First Tranche of Private Placement of Shares 20

Mologen to Raise USD15.2 Million in Rights Offering Shares 21

Mologen Raises USD31 Million in Offering of Shares 22

Mologen Raises USD21.2 Million in Private Placement of Shares 23

Mologen Raises USD27 Million in Private Placement of Shares 24

Debt Offering 25

Mologen Raises USD5.2 Million in Placement of 6% Convertible Bonds Due 2025 25

Mologen AG-Key Competitors 26

Mologen AG-Key Employees 27

Mologen AG-Locations And Subsidiaries 28

Head Office 28

Recent Developments 29

Financial Announcements 29

Nov 09, 2017: Nine-month result of MOLOGEN: key milestones reached in clinical studies, funding and licensing negotiations 29

Corporate Communications 31

Aug 01, 2018: Dr Ignacio Faus appointed as new CEO of MOLOGEN 31

Feb 13, 2017: MOLOGEN: Dr Matthias Baumann MD appointed as new Chief Medical Officer 32

Government and Public Interest 33

Oct 31, 2017: GHIT Fund Accelerates Promising Efforts to Find New Treatments, Vaccines and Diagnostics for Malaria, Tuberculosis, Leishmaniasis and Mycetoma 33

Product News 36

02/16/2017: MOLOGEN: New positive data on lefitolimod in HIV 36

01/10/2017: MOLOGEN: Grant to collaboration partner for combination study in HIV with lead product lefitolimod 37

Clinical Trials 38

Jan 23, 2017: MOLOGEN: Combination data of the TLR9 agonist Lefitolimod with checkpoint inhibitors in preclinical tumor models 38

Other Significant Developments 39

Apr 25, 2018: MOLOGEN reached key strategic milestones and successfully implements capital measures in 2017 39

Mar 22, 2017: MOLOGEN: New strategic orientation, successful capital measures and notable study progress in 2016 41

Appendix 43

Methodology 43

About GlobalData 43

Contact Us 43

Disclaimer 43


List Of Figure

List of Figures

Mologen AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Mologen AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Mologen AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Mologen AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Mologen AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Mologen AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Mologen AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Mologen AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Mologen AG, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Mologen AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Mologen AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Mologen AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Mologen AG, Deals By Therapy Area, 2012 to YTD 2018 9

Mologen AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Mologen to Raise USD0.6 Million in First Tranche of Private Placement of Bonds 11

Mologen to Raise up to USD14.9 Million in Private Placement of Convertible Bonds 12

Mologen Enters into Agreement with The University of Texas MD Anderson Cancer Center 13

Oncologie Expands Licensing Agreement with Mologen for lefitolimod 14

iPharma to Enter into Licensing Agreement with Mologen for Lefitolimod 16

Mologen Raises USD2.3 Million in Private Placement of Shares 17

Mologen Raises USD3.8 Million in Rights Offering of Shares 18

Mologen to Raise USD6.2 Million in Rights Offering Shares 19

Mologen Raises USD0.7 Million in First Tranche of Private Placement of Shares 20

Mologen to Raise USD15.2 Million in Rights Offering Shares 21

Mologen Raises USD31 Million in Offering of Shares 22

Mologen Raises USD21.2 Million in Private Placement of Shares 23

Mologen Raises USD27 Million in Private Placement of Shares 24

Mologen Raises USD5.2 Million in Placement of 6% Convertible Bonds Due 2025 25

Mologen AG, Key Competitors 26

Mologen AG, Key Employees 27

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Mologen AG, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.